Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Feb 2;129(5):643-649.
doi: 10.1182/blood-2016-09-738625. Epub 2016 Nov 29.

A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD

Gérard Socié  1   2   3 , Stéphane Vigouroux  4 , Ibrahim Yakoub-Agha  5 , Jacques-Olivier Bay  6 , Sabine Fürst  7 , Karin Bilger  8 , Felipe Suarez  9 , Mauricette Michallet  10 , Dominique Bron  11 , Philippe Gard  12 , Zakaria Medeghri  12 , Philippe Lehert  13 , Chinglin Lai  14 , Tim Corn  15 , Jean-Paul Vernant  16
Affiliations
Free article
Clinical Trial

A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD

Gérard Socié et al. Blood. .
Free article

Abstract

Treatment of steroid-resistant acute graft-versus-host disease (GVHD) remains an unmet clinical need. Inolimomab, a monoclonal antibody to CD25, has shown encouraging results in phase 2 trials. This phase 3 randomized, open-label, multicenter trial compared inolimomab vs usual care in adult patients with steroid-refractory acute GVHD. Patients were randomly selected to receive treatment with inolimomab or usual care (the control group was treated with antithymocyte globulin [ATG]). The primary objective was to evaluate overall survival at 1 year without changing baseline allocated therapy. A total of 100 patients were randomly placed: 49 patients in the inolimomab arm and 51 patients in the ATG arm. The primary criteria were reached by 14 patients (28.5%) in the inolimomab and 11 patients (21.5%) in the ATG arms, with a hazard ratio of 0.874 (P = .28). With a minimum follow-up of 1 year, 26 (53%) and 31 (60%) patients died in the inolimomab and ATG arms, respectively. Adverse events were similar in the 2 arms, with fewer viral infections in the inolimomab arm compared with the ATG arm. The primary end point of this randomized phase 3 trial was not achieved. The lack of a statistically significant effect confirms the need for development of more effective treatments for acute GVHD. This trial is registered to https://www.clinicaltrialsregister.eu/ctr-search/search as EUDRACT 2007-005009-24.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

Associated data

LinkOut - more resources